When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils , we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation. Now, roughly 16 months later, the startup is in talks to raise new funding at a $20 billion to $30 billion valuation, Axios reported . It’s not clear who is leading the new…
Why this update matters
This developing story is relevant for readers tracking technology because it reflects fresh changes from the original source and signals where attention is shifting next.
Key details
The report was collected automatically and prepared for publication with a newsroom workflow that focuses on clarity, search visibility, and quick understanding.
Readers should review the original source for direct statements, official notices, and any later corrections or additions as the story evolves.
Related coverage
Continue reading with more reporting from the same topic cluster.